Folks, check out this nice work: Over the past decade, #Precisionmedicine has been dominated by genomics platforms. Today, targeted #proteomics platforms like #somalogic, #OLINK, and #Hyperplex enable comprehensive profiling of patients before and during therapeutic interventions. Recently, #OLINK assays have been used to quantify protein plasma levels in longitudinal studies. The authors show that this high-content analytical platform can be extended for simultaneous analysis of ~700 unphosphorylated proteins by introducing massively parallel sequencing. The authors describe an approach suitable for comprehensive protein profiling, allowing stratification and monitoring of patients during treatment. Check out the original publication (Nature Communications) at Zhong, W., Edfors, F., Gummesson, A. et al. Next-generation plasma proteome profiling to monitor health and disease. Nat Commun 12, 2493 (2021).
Combine OLINK plasma analysis with Hyperplex 1,250-plex cell/tissue analysis. Hyperplex quantifies >800 unphosphorylated and >400 phosphorylated protein in parallel. The assay is easily customizable to your needs and additional antibodies can be added to the panel. Benefit from expert-curated biomarkers panels, pathway, signaling network analysis, and disease-centric panels.
